Ginkgo Bioworks (DNA) Expected to Release Earnings on Thursday

Ginkgo Bioworks (NYSE:DNA) is expected to be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.8950) per share and revenue of $24.85 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:30 PM ET.

Ginkgo Bioworks (NYSE:DNA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.21) by ($0.18). Ginkgo Bioworks had a negative return on equity of 56.08% and a negative net margin of 215.41%.The firm had revenue of $19.00 million during the quarter, compared to analysts’ expectations of $42.93 million.

Ginkgo Bioworks Stock Performance

Shares of Ginkgo Bioworks stock opened at $7.62 on Thursday. Ginkgo Bioworks has a 52-week low of $5.37 and a 52-week high of $17.58. The stock’s 50-day simple moving average is $8.79 and its 200 day simple moving average is $8.36. The stock has a market capitalization of $497.41 million, a P/E ratio of -1.42 and a beta of 1.77.

Analyst Ratings Changes

DNA has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ginkgo Bioworks in a research report on Friday, July 17th. Wall Street Zen lowered shares of Ginkgo Bioworks from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. One investment analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $8.50.

Institutional Investors Weigh In On Ginkgo Bioworks

A number of institutional investors and hedge funds have recently bought and sold shares of DNA. California State Teachers Retirement System increased its holdings in shares of Ginkgo Bioworks by 35.1% in the 3rd quarter. California State Teachers Retirement System now owns 36,030 shares of the company’s stock worth $525,000 after buying an additional 9,356 shares during the last quarter. Inspire Investing LLC raised its position in shares of Ginkgo Bioworks by 81.4% during the 4th quarter. Inspire Investing LLC now owns 57,293 shares of the company’s stock valued at $476,000 after buying an additional 25,716 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Ginkgo Bioworks by 63.4% during the 4th quarter. Wells Fargo & Company MN now owns 52,135 shares of the company’s stock worth $433,000 after acquiring an additional 20,235 shares during the last quarter. Edgewood Management LLC bought a new stake in shares of Ginkgo Bioworks during the 4th quarter worth $416,000. Finally, Sender Co & Partners Inc. bought a new stake in shares of Ginkgo Bioworks during the 2nd quarter worth $312,000. 78.63% of the stock is owned by hedge funds and other institutional investors.

About Ginkgo Bioworks

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.